Pharmacology is a very crucial element in the science of human health and diseases. Since this field is mainly involved in the development, testing and availing of human drugs, critical studies are often made in order to ensure that medicine in all markets are safe for each intended purpose of use in humans. It is therefore basically important to understand the relationship between drugs and the human body and by this we mean how pharmaceutical products react within the human body when it comes to fighting diseases and boosting immunity. In order to get this, researchers take into consideration the manner in which human bodies interact with various kinds of medicine. How drugs get absorbed and utilised within the body involves a number of metabolic processes and the process of metabolism is greatly driven by a number of enzymes. Enzymes can either be microsomal with the hepatic enzyme playing the greatest role and often called drug enzyme or non-microsomal enzymes which are quite specific in such a way that they only metabolise drugs with certain structure and content composition. For this study, we shall be looking at how to develop human immunity within the intestinal system considering that there have been a number of viral organisms in the human gut identified by scientists over the last years of research. Microbes evidently determine the level of individual health and wellbeing since how they interact with host cells determines their level of positive or negative effectiveness.

Weiyi Sun, Yiwen Fang, Yujia Hong, Sizheng Sheng, Haoyang Xuan, Qi Zhang. Homology study between human drug metabolizing enzymes and intestinal microbial metabolizing enzymes. Academic Journal of Medicine & Health Sciences (2021) Vol. 2, Issue 1: 69-72. https://doi.org/10.25236/AJMHS.2021.020112.

[1] Kobayashi S;Shinohara M;Nagai T;Konishi Y.Transport mechanisms for soy isoflavones and microbial metabolites dihydrogenistein and dihydrodaidzein across monolayers and membranes, Bioscience, biotechnology, and biochemistry,2013,77,2210-7.

[2] Stojančević M;Bojić G;Salami HA;Mikov M.The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs,Current issues in molecular biology,2014,16,55-68.

[3] Mallick P;Taneja G;Moorthy B;Ghose R.Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions,Expert opinion on drug metabolism & toxicology,2017,13,605-616.

[4] KA;Pellock SJ;Patterson LM;Creekmore BC;Isenberg HN;Bahethi RR;Bhatt AP;Liu J;Gharaibeh RZ;Redinbo MR. An Atlas of β-Glucuronidases in the Human Intestinal Microbiome, Structure (London, England : 1993),2017,25,967-977.e5.

[5] Choi MS;Yu JS;Yoo HH;Kim DH.The role of gut microbiota in the pharmacokinetics of antihypertensive drugs,Pharmacological research,2018,130,164-171.

[6] Zimmermann M;Zimmermann-Kogadeeva M;Wegmann R;Goodman AL.Mapping human microbiome drug metabolism by gut bacteria and their genes, Nature,2019, 570,462-467.

[7] Li J;Zhu HJ.Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters,2020,25.

[8] Kaur G;Gupta SK;Singh P;Ali V;Kumar V;Verma M.Drug-metabolizing enzymes: role in drug resistance in cancer,Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, 22, 1667-1680.

[9] Arun KB;Madhavan A;Sindhu R;Emmanual S;Binod P;Pugazhendhi A;Sirohi R;Reshmy R;Awasthi MK;Gnansounou E;Pandey A.Probiotics and gut microbiome - Prospects and challenges in remediating heavy metal toxicity,Journal of hazardous materials, Journal of hazardous materials, 2021,420,126-676.